Velan Capital Investment Management LP acquired a new stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 150,000 shares of the company's stock, valued at approximately $1,306,000. Kura Oncology accounts for about 1.1% of Velan Capital Investment Management LP's investment portfolio, making the stock its 16th biggest holding. Velan Capital Investment Management LP owned 0.19% of Kura Oncology at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in KURA. Vanguard Group Inc. lifted its stake in Kura Oncology by 14.6% in the fourth quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after acquiring an additional 615,211 shares during the last quarter. RA Capital Management L.P. purchased a new position in Kura Oncology in the fourth quarter worth approximately $38,769,000. Millennium Management LLC lifted its stake in Kura Oncology by 180.1% in the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after acquiring an additional 1,521,954 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Kura Oncology by 35.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock worth $12,419,000 after acquiring an additional 372,196 shares during the last quarter. Finally, Prosight Management LP lifted its stake in Kura Oncology by 87.9% in the fourth quarter. Prosight Management LP now owns 1,325,000 shares of the company's stock worth $11,541,000 after acquiring an additional 619,891 shares during the last quarter.
Analyst Ratings Changes
A number of brokerages recently issued reports on KURA. Barclays decreased their price target on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Mizuho cut their price objective on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, May 19th. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a report on Tuesday, April 8th. Finally, JMP Securities reissued a "market outperform" rating and set a $28.00 price objective on shares of Kura Oncology in a report on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and a consensus target price of $24.50.
Check Out Our Latest Stock Report on Kura Oncology
Kura Oncology Stock Performance
KURA traded down $0.60 during trading on Friday, hitting $5.64. The stock had a trading volume of 2,677,684 shares, compared to its average volume of 1,194,809. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market capitalization of $488.28 million, a P/E ratio of -2.39 and a beta of 0.50. The company's 50-day moving average price is $6.30 and its 200 day moving average price is $8.45. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $23.48.
Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. On average, equities research analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.
About Kura Oncology
(
Free Report)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Articles
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
